News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Jersey's Immune Response BioPharma, Inc. Unveils Plans To Develop In House Sales Force For HIV Blockbuster Remune


8/7/2014 6:56:26 AM

New Jersey's Immune Response BioPharma, Inc. Unveils Plans To Develop In House Sales Force For HIV Blockbuster Remune New Jersey's Immune Response BioPharma, Inc. Unveils Plans To Develop In House Sales Force For HIV Blockbuster Remune

August 7, 2014
By Krystle Vermes, BioSpace.com Breaking News Staff

Today, New Jersey-based Immune Response BioPharma, Inc. announced its plans to create an in-house sales force for Remune, its HIV vaccine.

Remune is a therapeutic vaccine that is designed to block the immune system’s response to HIV antigens in people with the virus. The vaccination consists of dead HIV-1 particles that have been emulsified with Incomplete Freund’s Adjuvant, a mixture of mannide mono-oleate and a highly purified mineral oil.

In past trials, Remune has shown positive results in HIV-1 infected patients who were undergoing treatment. Previous tests show that Remune may also be administered safely in combination with other antiviral drugs.

"IRBP plans to develop its own sales force for Remune HIV/AIDS vaccine once the FDA approves our BLA application,” said IRBP CEO David Buswell. “Once approved and cleared for marketing authorization by the FDA, the teller window will open for us we may go it alone or partner with several big pharma players. We have an infrastructure in place to handle CGMP manufacturing with a total of six vendors.”
  Related Jobs  
  Research Associate - Regeneron Pharma
  Scientist / Assoc. Manager - Regeneron Pharma
  Research Associate - Regeneron Pharma
  Postdoctoral Fellow - Pfizer
  Research Associate - Bristol-Myers Squibb
  Research Scientist - Gilead Sciences
  View More Jobs


In the past, Remune has been administered to more than 2,000 patients in approximately 25 separate clinical trials. It has been well tolerated by patients, giving it a positive safety profile. Remune is also easy to give to patients through an injection in the deltoid muscle.

Clinical studies of Remune have induced an HIV-specific response, which researchers believe is necessary to controlling HIV replication. Patients receiving injections of Remune have demonstrated improvements in their percentage of CD4 cells, HIV-1 DNA in PBMCs, and weight.

“Those who bet against IRBP will lose and lose badly, especially those big pharma HIV drug makers,” Buswell continued. “They are like the dinosaur soon headed to extinction, they are goners and doomed once Remune is approved. I would get off those drugs if I had HIV once Remune is available, they are risky and too toxic to take indefinitely."

IRBP has a goal of becoming the world leader in saving lives through vaccine technology. The company currently owns 100 percent of its drugs, treatments and vaccines through patents. IRBP believes that Remune should be considered a vital part of any treatment course for HIV/AIDS because of its proven track record in increasing the production of CD4+ T cell counts.

Read more recent drug product news .

Read at BioSpace.com


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES